ea0032p1081 | Thyroid cancer | ECE2013
Fallahi Poupak
, Ferrari Silvia Martina
, Bocci Guido
, La Motta Concettina
, Ruffilli Ilaria
, Di Domenicantonio Andrea
, Corrado Alda
, Mancusi Caterina
, Danesi Romano
, Da Settimo Federico
, Miccoli Paolo
, Antonelli Alessandro
Introduction: CLM29, a pyrazolo[3,4-d]pyrimidine compound, inhibits several targets (including the RET tyrosine kinase, epidermal growth factor receptor, vascular endothelial growth factor receptor and has an anti-angiogenic effect). Recently it has been shown to inhibit proliferation and migration in primary papillary dedifferentiated thyroid cancer cells. The aim of this study is to evaluate the anti-tumor activity of CLM29 in medullary thyroid cancer (MTC).<p c...